(Q44358008)

2 December 2017

Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study (English)

1 reference

2 December 2017

7

Douglas G Altman

1 reference

2 December 2017

Tom Maishman

3

0 references

Louise Stanton

object named as

Louise Stanton

5

0 references

Diana Eccles

13

object named as

Diana Eccles

1 reference

2 December 2017

Ellen Copson

1

1 reference

2 December 2017

Bryony Eccles

2

1 reference

2 December 2017

Sue Gerty

4

1 reference

2 December 2017

Ramsey I Cutress

6

1 reference

2 December 2017

Lorraine Durcan

8

1 reference

2 December 2017

Peter Simmonds

9

1 reference

2 December 2017

Gill Lawrence

10

1 reference

2 December 2017

Louise Jones

11

1 reference

2 December 2017

Judith Bliss

12

1 reference

2 December 2017

POSH Study Steering Group

14

1 reference

2 December 2017

language of work or name

English

0 references

publication date

30 May 2013

1 reference

Journal of the National Cancer Institute

2 December 2017

1 reference

2 December 2017

105

1 reference

2 December 2017

13

1 reference

2 December 2017

978-988

1 reference

The relation between survival and age at diagnosis in breast cancer.

2 December 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Breast cancer in young women: poor survival despite intensive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Effects of young age at presentation on survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Very young women (<35 years) with operable breast cancer: features of disease at presentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Younger age as a prognostic indicator in breast cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Breast cancer in very young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Women age < or = 35 years with primary breast carcinoma: disease features at presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

The impact of young age on breast cancer outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Correction: PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Adjuvant therapy of the very young woman

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Factors influencing the effect of age on prognosis in breast cancer: population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJT134

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJT134

1 reference

2 December 2017

1 reference